The shift from merely documenting the slow decline of the human body to actively engineering its
Modern oncology has long grappled with the frustrating reality that two patients with the exact
Ivan Kairatov has spent years at the intersection of biopharmaceutical innovation and rare disease research, witnessing firsthand how genomic technologies evolve from experimental tools to life-saving clinical standards. As an expert in the field, he brings a deep understanding of the systemic
The pharmaceutical landscape is currently witnessing a seismic shift as Eli Lilly commits a staggering seven billion dollars to acquire Kelonia Therapeutics, a move that signals a departure from traditional oncology treatments toward advanced genetic engineering. This acquisition, which includes an
The intricate dance of life within a human cell relies on more than just the genetic blueprints
The rapid integration of generative artificial intelligence into the sphere of personal health
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
Advanced Therapy Medicinal Products cannot be scaled the same way biologics were. The core
The End of the Old Biopharma Playbook The biopharmaceutical industry is confronting a structural
By 2030, the tissue-engineering market is projected to exceed $32.45 billion , reflecting a
The landscape of rare disease drug development is littered with clinical failures. For every
A surge of cardiometabolic risk among South Asians has demanded answers that Eurocentric datasets could not fully provide, and a new metabolite genome-wide association study in 3,000 Punjabi Sikh adults delivered evidence-rich clues that cut through long-standing gaps. By profiling 516 lipid
Healthcare facilities across the United States are currently navigating an era of unprecedented
The long-standing clinical assumption that colorectal cancer primarily strikes the elderly is
